Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
UK urges Vertex to accept ‘generous’ Orkambi funding offerVertex remains at loggerheads with NHS England over funding for Orkambi, but said it would consider the body’s Share XUK urges Vertex to accept ‘generous’ Orkambi funding offerhttps://pharmaphorum.com/news/nhs-vertex-orkambi-offer/
Market access for specialist medicines in the UK: the Price is Right?A recent pharmaphorum webinar brought four experts together to discuss the future of market access for specialist medicines Share XMarket access for specialist medicines in the UK: the Price is Right?https://pharmaphorum.com/articles/market-access-for-specialist-medicines-in-the-uk-the-price-is-right/
